Janssen Search
Search results
Janssen Reports Positive Topline Phase 2 Results for Nipocalimab in Pregnant Individuals at High Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
Feb 06, 2023 United States There are currently no approved therapeutics for the treatment of HDFN which, in severe cases, can cause life-threatening anemia in the fetus SPRING HOUSE, PENNSYLVANIA, February 6, 2023 – The Janssen Pharmaceutical Companies ...
Biljana Naumovic
Biljana Naumovic Worldwide Vice President Global Commercial Strategy Oncology Biljana Naumovic is the Worldwide Vice President, Global Commercial Strategy, Oncology for the Janssen Pharmaceutical Companies of Johnson & Johnson. Working in ...
Social Innovation Summit
Inspiring Behavior Changes at the Social Innovation Summit Healthcare systems around the world are struggling to deliver accessible and affordable care amid increased demand from a growing middle class, aging populations and changes in our natural ...
Autoantibody Pathway: Pioneering Novel Science to Address Unmet Patient Therapeutic Need
Autoantibody Pathway: Pioneering Novel Science to Address Unmet Patient Therapeutic Need Janssen Immunology has expanded our pipeline and portfolio beyond anti-cytokine antibody treatments, to include the development of novel therapeutics to treat a ...
Collaborating with Karolinska Institutet for Advanced Real-World Data Analysis
Article Block Text: Article Type: Other Collaborating with Karolinska Institutet for Advanced Real-World Data Analysis A collaborative initiative with Karolinska Institutet and Janssen for research and development for a program in Real World Evidence ...
Cardiovascular, Metabolism & Retina
Cardiovascular & Metabolism Cardiovascular & Metabolism Micro Pancreas Pancreas Cardiovascular, Metabolism & Retina Discovering Underlying Mechanisms Research & Development: Accelerating the Molecule Commercialization of Cardiovascular ...
Steve Wooding, M.D.
STEVE WOODING, M.D. HEAD, GLOBAL COMMERCIAL STRATEGY ORGANIZATION Steve Wooding, M. D., is Head, Global Commercial Strategy Organization (GCSO) and Market Access Organization, a position he assumed in June 2015. He is a member of the Pharmaceuticals Group ...
European Commission Approves Reduced Dosing Frequency for Janssen’s Bispecific Antibody TECVAYLI®▼ (teclistamab)
Aug 18, 2023 Belgium Teclistamab, the first BCMA-targeting bispecific antibody to receive approval in Europe, maintained deep and durable responses, with reduced onset of Grade 3 or higher infections, in eligible patients with relapsed and refractory ...
Janssen Seeks European Commission Approval of a New Indication for CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) for the Earlier Treatment of Patients with Relapsed and Refractory Multiple Myeloma
May 25, 2023 Belgium Application to the European Medicines Agency is supported by data from the Phase 3 CARTITUDE-4 study, which evaluated the safety profile and efficacy of cilta-cel in the treatment of patients who received one to three prior lines of ...
The Patients Are Waiting – Paul Janssen
We are driven by our belief that patients are waiting and there is no time to waste. Dr. Paul Janssen at the University of Ghent, Belgium, laboratories in the early 1950s. There he obtained his Ph.D. in Medicine in 1951 and his Ph.D. in Pharmacology in ...